$41.50
0.390.95%
Last update: Oct 16, 4:50 PM
$41.44
0.330.8%
Teva Pharmaceutical Industries Ltd
TEVANYSE
Teva Pharmaceutical Indus (TEVA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Teva Pharmaceutical Indus (TEVA) last issued guidance on July 29, 2026 for fiscal year 2026. The company guided earnings per share in the range of $1.91 - $2.11, compared to a consensus EPS estimate of $2.17. Teva Pharmaceutical Indus also guided revenue in the range of $16.5B - $16.85B for the period.
Compared to prior guidance, Teva Pharmaceutical Indus lowered its EPS outlook from a previous range of $2.57 - $2.77. On the revenue side, the company maintained its revenue forecast from a prior range of $16.4B - $16.8B.
Teva Pharmaceutical Indus has issued 19 guidance updates between November 3, 2022 and July 29, 2026. During this period, the company raised its outlook 6 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.41 | $0.46 | $0.63 | $0.67 |
| Actual | $0.02 | $0.53 | $0.96 | $0.78 |
| Surprise | -95.1% | +15.2% | +52.4% | +16.4% |
| Revenue | ||||
| Estimate | $4.07B | $3.81B | $4.33B | $4.34B |
| Actual | $4.14B | $3.98B | $4.71B | $4.48B |
| Surprise | +1.82% | +4.41% | +8.77% | +3.20% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.72 | $0.76 | $0.62 | $0.70 |
| Revenue | ||||
| Consensus | $4.25B | $4.24B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $0.02 | $0.41 | -95.1 % |
| Q1 | Apr 29, 2026 | $0.53 | $0.46 | 15.2 % |
| Q4 | Jan 28, 2026 | $0.96 | $0.63 | 52.4 % |
| Q3 | Nov 5, 2025 | $0.78 | $0.67 | 16.4 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $4.14B | $4.07B | 1.82 % |
| Q1 | Apr 29, 2026 | $3.98B | $3.81B | 4.41 % |
| Q4 | Jan 28, 2026 | $4.71B | $4.33B | 8.77 % |
| Q3 | Nov 5, 2025 | $4.48B | $4.34B | 3.20 % |
